RAS pathway activation and an oncogenic RAS mutation in sporadic pilocytic astrocytoma.

Department of Neurology, Washington University School of Medicine, St. Louis, MO 63110, USA.
Neurology (Impact Factor: 8.3). 11/2005; 65(8):1335-6. DOI: 10.1212/01.wnl.0000180409.78098.d7
Source: PubMed
  • [Show abstract] [Hide abstract]
    ABSTRACT: Low-grade gliomas represent the most frequent brain tumors arising during childhood. They are characterized by a broad and heterogeneous group of tumors that are currently classified by the WHO according to their morphological appearance. Here we review the clinical features of these tumors, current therapeutic strategies and the recent discovery of genomic alterations characteristic to these tumors. We further explore how these recent biological findings stand to transform the treatment for these tumors and impact the diagnostic criteria for pediatric low-grade gliomas.
    Biochimica et Biophysica Acta (BBA) - Reviews on Cancer 01/2014; · 9.03 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Neurofibromatosis type 1 is an inherited cancer predisposition syndrome in which 15–20% of children develop optic gliomas. Most of these tumors form along the optic nerve and chiasm, where they can cause decreased visual function and endocrine dysfunction. Advances in mouse modeling of this disease have created tractable models to study the role of specific genetic alterations, deregulated intracellular signaling pathways and non-neoplastic cells in the development of optic gliomas. These small-animal models have been used as platforms to discover new targets for drug design and to evaluate the efficacy of these potential anticancer treatments prior to clinical trials in children with optic glioma.
    Expert Review of Ophthalmology 01/2014; 6(3).
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Background The body of disease mutations with known phenotypic relevance continues to increase and is expected to do so even faster with the advent of new experimental techniques such as whole-genome sequencing coupled with disease association studies. However, genomic association studies are limited by the molecular complexity of the phenotype being studied and the population size needed to have adequate statistical power. One way to circumvent this problem, which is critical for the study of rare diseases, is to study the molecular patterns emerging from functional studies of existing disease mutations. Current gene-centric analyses to study mutations in coding regions are limited by their inability to account for the functional modularity of the protein. Previous studies of the functional patterns of known human disease mutations have shown a significant tendency to cluster at protein domain positions, namely position-based domain hotspots of disease mutations. However, the limited number of known disease mutations remains the main factor hindering the advancement of mutation studies at a functional level. In this paper, we address this problem by incorporating mutations known to be disruptive of phenotypes in other species. Focusing on two evolutionarily distant organisms, human and yeast, we describe the first inter-species analysis of mutations of phenotypic relevance at the protein domain level. Results The results of this analysis reveal that phenotypic mutations from yeast cluster at specific positions on protein domains, a characteristic previously revealed to be displayed by human disease mutations. We found over one hundred domain hotspots in yeast with approximately 50% in the exact same domain position as known human disease mutations. Conclusions We describe an analysis using protein domains as a framework for transferring functional information by studying domain hotspots in human and yeast and relating phenotypic changes in yeast to diseases in human. This first-of-a-kind study of phenotypically relevant yeast mutations in relation to human disease mutations demonstrates the utility of a multi-species analysis for advancing the understanding of the relationship between genetic mutations and phenotypic changes at the organismal level.
    BMC Genomics 14(3). · 4.40 Impact Factor